Global Drug Delivery Challenges Explained

Two men, Nick A. (left) and Nigel (right), sit at a white table, engaging in a lively and friendly conversation. Both wear checkered shirts and lavalier microphones, suggesting a filmed discussion or interview. Nick holds tissue samples in one hand and gestures animatedly, while Nigel smiles in response. Each has a white mug labeled with their name and a purple star logo. The background is a bright white, creating a clean and professional studio setting.
Resources

Global Drug Delivery Challenges Explained

Topic: Bio Break
YouTube video thumbnail

In this episode of Bio Break, Nick Allan and Nigel Syrotuck dive into the surprising realities of global drug delivery. While medical devices often dominate development conversations, the way drugs are delivered across regions can dramatically change how treatments succeed — or fail.

Nigel reflects on a trip to Italy where food sparked thoughts about oral drug delivery. In regions like Italy, pills and tablets are the most common approach. Larger countries also tend to prefer simple, scalable methods such as pills or injections. By contrast, smaller regions may be more open to specialized treatments that require more time or unique handling.

Regional Differences in Drug Delivery

Drug delivery methods are influenced not just by culture, but also by economics, insurance systems, and infrastructure. For example, biosimilars are more readily accepted in some countries depending on reimbursement structures. Meanwhile, large-scale programs — such as vaccine rollouts — highlight how fragile supply chains can be.

Cold Chain and Pandemic Lessons

Certain drugs, including attenuated vaccines, require strict cold chain maintenance. In developing regions, this presents a major challenge. The COVID-19 pandemic underscored this issue when millions of doses expired due to distribution and storage limitations. As Nick and Nigel note, a drug designed for one part of the world may face barriers to adoption in another, depending on the delivery method.

Enjoying Bio Break? Sign up to get new episodes sent to your inbox.

Subscribe to Bio Break
Diagram showing medical device at the center connected to clinicians, patients, and regulatory bodies with text 'Who are we designing for?' highlighting stakeholder mapping in MedTech design.

Understanding Medical Device Stakeholders

Every phase of a device’s life cycle involves different people with distinct needs—from clinicians and patients to service technicians and regulatory bodies.

A fluorescent protein assay sample glows under UV light as part of medical device cleaning validation testing.

Fluorescent Protein Assay Testing in Medical Devices

Nick Allan and Nigel Syrotuck explain how a fluorescent protein assay helps engineers measure contamination and cleaning performance in medical devices.

Engineer assembling electronic components during medical device design transfer process.

Bridging the Design-to-Manufacturing Gap in Medical Devices

Your team is ready for design validation. The prototype performs well, test plans are in motion, and everything points to a smooth handoff to manufacturing. Then your partner calls with bad news: they can’t build the device as designed.

Contract Manufacturer Rejection - Engineering team reviews early-stage medical device design and manufacturability during a design transfer meeting at StarFish Medical.

When the CM Says No: What to Do When Your Contract Manufacturer Rejects Your Early-Stage Build

You’ve cleared the toughest engineering hurdles and proven your design works. Then, just as you prepare to scale, your contract manufacturer turns you down.